February 28, 2020. Portland, Oregon. Nobilis Therapeutics has announced that it has fully endorsed the grant application to conduct an Investigator-Initiated Clinical Trial of NBTX-001 in patients with Obsessive Compulsive Syndrome (OCD). The grant has been submitted to International OCD Foundation (IOCDF) by Dr. Brian Brennan of Harvard’s McLean Hopsital. Dr. Brennan is the medical director of the Obsessive Compulsive Disorder Institute at McLean Hospital—a world-renowned intensive residential treatment facility for patients with severe OCD and related disorders. He has published extensively on the use of neuroimaging to investigate neurochemical and neurobiological abnormalities underlying psychiatric disorders such as OCD and depression.
Exposure and response prevention (ERP), the gold-standard cognitive behavioral treatment for obsessive-compulsive disorder (OCD), is predicated on existing evidence of deficient fear extinction in patients with OCD. The proposed mechanism of action of NBTX-001 has to do with its perceived ability to enhance and expedite response to ERP based on its ability to block fear memory reconsolidation.
“While ERP is effective in a majority of OCD patients, about 30% of patients who complete a course of ERP continue to experience significant symptoms, and an additional 20% with access to ERP either drop out prematurely or refuse treatment altogether,” commented Dr. Vlad Bogin, CEO of Nobilis Therapeutics. “We hope that by adding a safe therapeutic devoid of psychomimetic side effects we can significantly reduce the overall OCD symptoms compared to placebo administration,” he concluded.
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable controlled device administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric, neurodegenerative and other diseases and leverages the experience of its international team that has studied this technology in the treatment of over 2500 patients for conditions ranging from panic attacks to substance abuse. Company’s first clinical trial in 81 patients with Panic Disorder showed significant signals of efficacy. In 2016 the Company entered into an exclusive licensing agreement with Harvard University on the use of NBTX-001 in PTSD and had a patent issued the next year. Of its 14 independently filed patents 3 have been issued. In January of 2019 the Company had entered into collaboration with Linde AG to support its medical device and clinical development program.
Vlad Bogin, MD, FACP
US Bancorp Tower, 111 S.W. Fifth Avenue, Suite 3150, Portland, OR, 97204
Tel: (971) 229-1679